ADVANCED SOLID TUMOR

eFT508 in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone (eFFECTOR)

Phase II

This study will evaluate the safety, tolerability, antitumor activity, and PK of eFT508 in subjects who have initiated anti-PD-1/anti-PD-L1 monotherapy and either developed progressive disease on therapy or have undergone more than 12 weeks of anti-PD-1/anti-PD-L1 therapy with no evidence of progressive disease or complete response. Subjects will continue their anti-PD-1/anti-PD-L1 therapy, which they had already initiated per standard of care according to the package insert, and then initiate eFT508 prior to their next scheduled anti-PD-1/anti-PD-L1 therapy.

Treatment agent: eFT508 + PD-1/PD-L1 Inhibitor Therapy
PI: Thomas Stanton, MD
Study Coordinator: Sabine Ucik // Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links: clinicaltrials.gov NCT No: NCT03616834

A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fruquintinib in Advanced Solid Tumors (Hutchison)

Phase I

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of fruquintinib in patients with advanced solid tumors. Multiple doses fruquintinib will be used to investigate the metabolite profile of fruquintinib in the plasma of patients with advanced solid tumors.

Treatment agent: Fruquintinib
PI: Thomas Stanton, MD
Study Coordinator: Sabine Ucik // Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links: clinicaltrials.gov NCT No: NCT03251378

Our Locations